

# From Bones to Behemoths Understanding Paleontology's Big Discoveries

## Saurav Sahoo\*

Physics and Applied Mathematics Unit, Banaras Hindu University, India

### Abstract

Paleontology, the study of ancient life through fossils, has yielded numerous groundbreaking discoveries that have reshaped our understanding of Earth's history and the evolution of life. This article explores the key milestones and insights in paleontology, from its or ´ preservation efforts in safeguarding our paleont

Pal o⊠l Ba,KI i o⊠th KI Bar a≞ i oKli KI il, a la a Blabi Bli a inabla b Bli inBlBan Bl n al bli in 🛛 🖾 Ea 🖾 🖾 i 🖾 🕅, n ali.IBAiafil 🛛 aBA l in K 1 a - xMa 🛛 a**K**an i in al abl in i 🛽 K in**N N** l⊠a lia la∩⊠F K bl b innin il դեն հեն nbain i i l al in a al ı⊠l Bara ո⊠ւոallba xaւ n, Kan in K i [1]. na⊠ al

Pal n 🛛 🕅 🕅 🖌 🖬 i n 🖾 fi 🖾 🕅 an i n 🖾 li 🖾 il, i iMBBab ⊠⊠⊠ Kan a a K Ka ոk K anik Ka n in na⊠ al 🛚 na in binnin il դ⊠եղ 🛛 1.F a a∩ ⊠്റിആ3, aി∩⊠ി⊠9 a K n- a🕅 a l n Ma lka il 🛛 K i⊠ili.ia⊠dl l i, 🛛 ain i🛛 in**M M** al al ı⊠l Sood bi i 1 🖬 n R a 🌆 i n n K а 🖗 а [2].

a b 🛙 a ina⊠in i⊠ al n⊠l pai i⊠ i b ina, 🛙 a⊠ ⊠a⊠ 🛚 a -in iin all l al 🛚 Ea 🖾 . Y 🖾 🖬 fil 🕮 🛛 an 🛛 🖾 n а а а ina, in in i 🛛 in 🖾 🖬 ba Ba Ba l 🛛 n an ⊠lia⊠ia⊠ b li ⊠a⊠a ann illi a ipa [3].

lanalBai, an inn aMa xaa 🛛 🕰 🕮, a 🖌 ni , al n⊠l i⊠a n a⊠ K a 🛙 a il ⊠a⊠ a դ 🖪 հրունդ Ea 🛚 i 🛛 🖼 F K а an in 🛛 i b 🖾 🖾 a KAKK i i ain

Kan Kaka n Kan Kan [9].

#### **Conservation and preservation**

al n 🛛 🛛 🙀 nMn M M X N K а 🛙 Α n, R ղ 🖬 դ 🛛 i Man in il i in i⊠ ո ատեն ու Мաստ 🗗 🗹 1 🕅 🛛 i nifi an🛛 R il i⊠ a 🛚 a 🖾 .n⊠lia⊠ , an ill al n. 1 an i¤.Pal a⊠l i⊠ il 🛙 a M 1 n**R** an i⊠ , ∩ in KaKK M ain a ibl in⊠fi i⊠h 🕅 📓 an a 🛛 n. B 🛱 in al n⊠l i al , n**M**n 🛙 lan a Man in i K a🛛 n an M n. i ո 🛛 🖉 a ո n⊠ ia⊠.

## Discussion

Pal ı⊠l Ka⊠bi i i a Man Man in £ Ea 🛛 🖾 i 🗗 🖓 a 🕰 🕅 1 🖬 n li. i i an a ₿i,  $l \mathbf{x}$ K i an £ ani n⊠⊠a⊠a R li lan 🛙 In x X n X n - fi а l in**M** M ⊠i i in, an i li a🖬 n al …⊠l Ba⊠a finin.

∩**⊠l ⊠⊠** K X in nK i а n, al n**X**. аK i∩a⊠ K i ni a nifi n🛛 а i in 🛛 M i Ea, la in b lan ia a i il а a 🛿 a🖾 in 🛛 🖾 an 🖾 ⊠a⊠ K bli ali 1 🗹 📓 in a il, al ı⊠l i⊠ n 🛛 🖌 a а 🗹 i ana 🛛 🖗 b a i , an liall, i in in al abl ia i 🛛 ia 🖾 🖾 aa i a 🖾 1.

1 🖬 n, .c⊠1 B3 R nМ Pal a ni 🛛 🖾 a 🗳 ifi a🛛 🗅 i in an i all in аi а illi n Sa . B 🛛 **K** Satia K il ani ் பிதி 🛛 வாட் பிதி 1 🗹 📖 a 🖼 🗹 n,⊠a R ŋ. n, i, an x l K ani i in 1 🖬 na 👼 MA M an fin in i ial i n X l 🛛 n an l l i a 🗷 🖪 i n 🗷 uu 🛛 all li in - 0 ⊠ in [10].

MEa 🛛 🖾 i 🖾 🙀, n x X a X a n⊠ a а ,lain 🛛 🖾 n 🛛 🛯 🕷 i a l bi i🚾 Pal labøf a i⊠al n**M**n M n 🛛 an in ⊠a⊠n ⊠i l in ா**⊠⊠** aாட் ந**⊠ தொ** . Boog 🛛 😡 մու ili ain, а in li 🛛 n 🕅 a 🛛 🕅 a🖾 i x⊠ո⊠ դaդ X Baaia a 🛛 x 🖾 a 🖾 a ı⊠α n⊠al l i al a al. Un i⊠ a⊠∩ K K a bi i iKK i 🖬 n an

ո**⊠հա**a, Kaliala an In nΜ а 1 🖬 ni K fi l K xkak n al n⊠l ⊠, nablin nK а Bail ili i a.Hi l 🛛 ni ain 🗹 ni a CT annin an la annin , all in Ma Ma Mali

a il in 🛛 🗠 🖾 i₿ 🛚 a a i a il.A ild nall R a an in⊠DNA anal⊠i, 1 la ni i <u>n</u> an 🛛 i 🛛 🕅 անուս 🛛 la⊠r n i R ani а - 0 n i

n⊠ 1 S n**M**n K M K M а 🛙 А al ŋ M in ŋ K il i⊠ an i n K i a ŋ a 🛛 n. Man 🙀 K 1 🛛 🛚 i nifi an 🖾 il i⊠ a n K аK 1 n⊠ li аØ an ,an ill al⊠a in . n⊠l i⊠a аK K аĦ n 🛛 🕅 i⊠ , Pal ni in a🛛 nal, an 🛛 i i ∩⊠fi, l⊠ al al [11]

## Conclusion

F i₿ bl b innin K i₿ n-aba i nK. al n**M** l ÿ а la a i Bal l in a in ŋ Man in R naK al 1. K K X il. al n⊠l i⊠ R nl R an i n⊠li alin a 1 fill а i⊠ Man a ilia.A K n Ma аØ ЬØ n ] ÿ an a , 🗹 fi l al n⊠l 😡 K i i а а an an Ĥ K K Ea 🛛 🖾 i i 🛛 🖗 F i £ K 🕱 bi R b n 🛛 b al n⊠ 1 i i in ina 🛱 i i 🕅 a n ili n li x⊠a lan 🛙

#### References

- Amale PN, Deshpande SA, Nakhate YD, Arsod NA (2018) Pharmacovigilance process in India: An overview. J Pharmacovigil 6:259.
- 2. Kim JH, Scialli AR (2011) Thalidomide: The tragedy of birth defects and the efective treatment of disease. Toxicol Sci 122: 1-6.
- 3. Routledge (1998) 150 years of Pharmacovigilance. Lancet 351: 1200-1201.
- Srivastava P, Kumar P, Sharma A, Upadhyay Y (2011) A review Pharmacovigilance importance and current regulations. Pharmacol Online 2: 1417-1426.
- Kalaiselvan V, Prasad T, Bisht A, Singh S, Singh GN, et al. (2014) Adverse drug reactions reporting culture in pharmacovigilance programme of India. Indian J Med Res 140:563-564.
- Craigle V (2007) MedWatch: The FDA safety information and adverse event reporting program. Journal of the Medical Library Association 95:224.
- Pacurariu AC, Coloma PM, Haren A, Genov G, Sturkenboom MC, et al. (2014) A description of signals during the frst 18 months of the EMA pharmacovigilance risk assessment committee. Drug safety 37: 1059-1066.
- Gould LA (2003) Practical Pharmacovigilance analysis strategies. Pharmacoepidemiology and drug safety 12:559-574.
- Tandon V, Mahajan V, Khajuria V, Gillani Z (2015) Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India. Indian J Pharmacol 47:65-71.
- Khattri S, Balamuralidhara V, Pramod KT, Valluru R, Venkatesh MP, et al. (2012) Pharmacovigilance regulations in India: a step forward. Clin Res Regul Af 29:41-45.
- Biswas P, Biswas AK (2007) Setting standards for proactive pharmacovigilance in India: the way forward. Indian J Pharmacol 39:124-128.